Please login to the form below

Not currently logged in
Email:
Password:

Sigma-Tau Pharmaceuticals appoints Dave Lemus chief operating officer

He takes over from Gregg Lapointe who has resigned

Dave Lemus has been appointed chief operating officer at Sigma-Tau Pharmaceuticals.

He joined the US rare diseases company in July 2011 as VP, finance and in his new role he takes over from Gregg Lapointe who has resigned.

President of Sigma-Tau Pharmaceuticals Professor Trevor Jones said: "We are delighted to appoint Dave to lead our efforts to expand the world-class rare disease business we have established in the US.

“Dave brings a wealth of relevant pharmaceutical and biotech experience from both the US and Europe. His appointment will serve to further strengthen our unwavering mission to serve the needs of rare disease patients."

Prior to joining Sigma-Tau Lemus was chief financial officer at German biotech company MorphoSys, where he launched Germany's first-ever biotechnology IPO in 1999.

Before this he held a variety of senior management roles at Hoffmann-La Roche and Lindt in Switzerland.

12th March 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...